iProXProteomicsXianwei WangHomo Sapienshttp://www.iprox.org/page/project.html?id=IPX0016598000Wangxianwei1116@126.comHenan Key Laboratory of Medical Tissue RegenerationiProXfalseProteomics of AC-16 cells treated with DOXDoxorubicin (DOX) is a potent chemotherapeutic agent, but its clinical use is limited by dose-dependent cardiotoxicity. To elucidate the molecular mechanisms underlying DOX-induced cardiomyopathy, we performed quantitative proteomic analysis on DOX-treated human AC-16 cardiomyocytes. The treatment group comprised AC-16 cells exposed to 0.2 µM DOX for 48 hours, with solvent-treated cells serving as the control.Mon Apr 13 00:00:00 BST 2026PXD0770629606